Anima's software can autonomously take a specific medical history, present potential diagnoses and suggested next steps to the clinic, and facilitate real-time collaboration among clinic staff. The company's main competitors include UK-based accuRx and US-based Memora Health and NexHealth. Anima's CEO, Shun Pang, a former doctor and self-taught software engineer, sees any company with a credible path to a 'care enablement' platform as a competitor. Despite the challenges of dealing with the NHS, Anima has made significant inroads due to its immediate impact and the unique background of its founder.
Key takeaways:
- UK startup Anima, a care enablement platform for healthcare clinics and hospitals, has raised a $12 million Series A funding round led by Molten Ventures, with participation from Hummingbird Ventures, Amino Collective, Y Combinator, and new angel investors.
- Anima's software allows clinic staff to process and file healthcare documents with a higher degree of automation compared to legacy systems, and can autonomously take a specific medical history.
- Anima is now used in 150 NHS clinics in England and has made encouraging inroads into the NHS, which is known to be notoriously difficult to deal with.
- Competitors in this space include UK-based accuRx, U.S.-based Memora Health, and NexHealth, with Anima's CEO seeing their real competitors as any company with a credible path to a care enablement platform.